Red blood cells from pluripotent stem cells for use in transfusion

Joanne C. Mountford, Emmanuel N. Olivier, Niove E. Jordanides, Paul De Sousa, Marc L. Turner

Research output: Contribution to journalReview article

8 Citations (Scopus)

Abstract

The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.

Original languageEnglish (US)
Pages (from-to)411-423
Number of pages13
JournalRegenerative Medicine
Volume5
Issue number3
DOIs
StatePublished - 2010
Externally publishedYes

Fingerprint

Pluripotent Stem Cells
Stem cells
Blood
Erythrocytes
Cells
Erythrocyte Transfusion
Suspensions
Cell Count
Safety
Therapeutics
Infection
Molecules
Human Embryonic Stem Cells

Keywords

  • Blood transfusion
  • Cell therapy
  • Current good manufacturing practice
  • Pluripotent stem cell
  • Red blood cell

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology
  • Medicine(all)

Cite this

Mountford, J. C., Olivier, E. N., Jordanides, N. E., De Sousa, P., & Turner, M. L. (2010). Red blood cells from pluripotent stem cells for use in transfusion. Regenerative Medicine, 5(3), 411-423. https://doi.org/10.2217/rme.10.22

Red blood cells from pluripotent stem cells for use in transfusion. / Mountford, Joanne C.; Olivier, Emmanuel N.; Jordanides, Niove E.; De Sousa, Paul; Turner, Marc L.

In: Regenerative Medicine, Vol. 5, No. 3, 2010, p. 411-423.

Research output: Contribution to journalReview article

Mountford, JC, Olivier, EN, Jordanides, NE, De Sousa, P & Turner, ML 2010, 'Red blood cells from pluripotent stem cells for use in transfusion', Regenerative Medicine, vol. 5, no. 3, pp. 411-423. https://doi.org/10.2217/rme.10.22
Mountford, Joanne C. ; Olivier, Emmanuel N. ; Jordanides, Niove E. ; De Sousa, Paul ; Turner, Marc L. / Red blood cells from pluripotent stem cells for use in transfusion. In: Regenerative Medicine. 2010 ; Vol. 5, No. 3. pp. 411-423.
@article{099bf4ebc1f94c6c89d65c7343498f29,
title = "Red blood cells from pluripotent stem cells for use in transfusion",
abstract = "The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.",
keywords = "Blood transfusion, Cell therapy, Current good manufacturing practice, Pluripotent stem cell, Red blood cell",
author = "Mountford, {Joanne C.} and Olivier, {Emmanuel N.} and Jordanides, {Niove E.} and {De Sousa}, Paul and Turner, {Marc L.}",
year = "2010",
doi = "10.2217/rme.10.22",
language = "English (US)",
volume = "5",
pages = "411--423",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "3",

}

TY - JOUR

T1 - Red blood cells from pluripotent stem cells for use in transfusion

AU - Mountford, Joanne C.

AU - Olivier, Emmanuel N.

AU - Jordanides, Niove E.

AU - De Sousa, Paul

AU - Turner, Marc L.

PY - 2010

Y1 - 2010

N2 - The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.

AB - The use of donated red blood cells in transfusion is a well-established cellular therapy. However, problems including insufficient supply, transfusion-transmitted infections and the need for immunological matching hamper even in the best services. These issues may be eliminated by using pluripotent stem cells to generate universal donor group O, Rhesus D-negative red blood cells. Human embryonic stem cells can be maintained and expanded indefinitely and can, therefore, produce the very large cell numbers required for this application. Red blood cell production is also an attractive goal for pluripotent stem cell-derived therapeutics because it is a well-characterized single cell suspension, lacking nucleated cells and with a low expression of HLA molecules. Much progress has been made; however, a number of challenges remain including scale-up, clinical effectiveness and product safety.

KW - Blood transfusion

KW - Cell therapy

KW - Current good manufacturing practice

KW - Pluripotent stem cell

KW - Red blood cell

UR - http://www.scopus.com/inward/record.url?scp=77952248233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77952248233&partnerID=8YFLogxK

U2 - 10.2217/rme.10.22

DO - 10.2217/rme.10.22

M3 - Review article

C2 - 20455652

AN - SCOPUS:77952248233

VL - 5

SP - 411

EP - 423

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 3

ER -